tiprankstipranks
pc:teenp

4TEEN4 Pharmaceuticals GmbH

4TEEN4 Pharmaceuticals GmbH is focused on reversing life-threatening shock and restoring organ function with procizumab, a first-in-class antibody that blocks circulating DPP3, a key pathological driver of mortality in shock. The company is conducting a Phase 2a study to evaluate procizumab's potential as a treatment for shock caused by acute cardiovascular and septic events, aiming to improve survival in critically ill patients.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$55M
Total Amount Raised$55M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$55M
Latest Funding Amount$55M
Latest Funding RoundSeries C
Latest Funding RoundSeries C
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Nov 13, 2025
Series C
$55.00M

Related News and Analysis